HUTCHMED Initiates Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors in China

3 years ago

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;…

Mainz Biomed Initiates Clinical Study to Evaluate Integrating Novel mRNA Biomarkers Into ColoAlert

3 years ago

Results to impact ColoAlert profile for FDA submission Provides opportunity for ColoAlert to achieve gold standard status as the premier…

Arcellx Announces Pricing of Initial Public Offering

3 years ago

GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the…

Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D

3 years ago

Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth…

Press Release: Strong 2021 sales and business EPS growth enabling increased investment in R&D

3 years ago

Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth…

Press release Biocartis Group NV: Disclosure of a transparency notification

3 years ago

PRESS RELEASE: REGULATED INFORMATION                                                                                4 February 2022, 07:00 CET Disclosure of a transparency notification Mechelen, Belgium, 4 February 2022 – Biocartis…

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

3 years ago

Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022Sub-analysis compared the immunogenicity of VLA15 in…

Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients

3 years ago

First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England Two children with early-onset MLD recently treated…

PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THIRD QUARTER ENDED DECEMBER 31, 2021 [UPDATED]

3 years ago

MINNEAPOLIS, MN, US, Feb. 03, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device…